Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TE-HA refers to two distinct but related entities in biotechnology and pharmacology. Most commonly, it is a chemical abbreviation for **Tetrazine-modified Hyaluronic Acid**, a critical component of the **click-crosslinked hyaluronic acid (Cx-HA)** hydrogel system. This system utilizes a biorthogonal Diels-Alder click crosslinking reaction between tetrazine (TE) and trans-cyclooctene (TC) to form injectable, self-healing hydrogels with prolonged residence times in vivo. These hydrogels are being investigated for applications in regenerative medicine, including intra-articular drug delivery for **rheumatoid arthritis** and **osteoarthritis**, as well as scaffolds for **bone tissue engineering**. Separately, in the context of oral medicine, **TE-HA MN** refers to a multifunctional microneedle (MN) patch formulation composed of **hyaluronic acid (HA)** and loaded with **triamcinolone acetonide (TA)** and **epidermal growth factor (EGF)**. This formulation is designed for the treatment of **recurrent aphthous stomatitis (RAS)**, where the microneedles provide rapid drug release and enhanced mucosal adhesion to promote ulcer healing and alleviate pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TE-HA.